Financials data is unavailable for this security.
View more
Year on year Gan & Lee Pharmaceuticals grew revenues 52.31% from 1.71bn to 2.61bn while net income improved from a loss of 439.52m to a gain of 340.07m.
| Gross margin | 72.92% |
|---|---|
| Net profit margin | 19.71% |
| Operating margin | 19.01% |
| Return on assets | 5.04% |
|---|---|
| Return on equity | 5.51% |
| Return on investment | 5.40% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Gan & Lee Pharmaceuticals fell by 110.89m. Cash Flow from Financing totalled 754.70m or 28.94% of revenues. In addition the company generated 109.45m in cash from operations while cash used for investing totalled 977.40m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 18.65 |
|---|---|
| Tangible book value per share | 16.81 |
More ▼
Balance sheet in CNYView more
| Current ratio | 8.04 |
|---|---|
| Quick ratio | 6.77 |
| Total debt/total equity | 0.0005 |
|---|---|
| Total debt/total capital | 0.0005 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 176.66%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 20.46% |
| EPS growth(5 years) | -20.15 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 129.12 |
More ▼
